|
Multivariate analysis of the factors associated with dispensation of celecoxib and rofecoxib versus traditional nonselective NSAIDs |
||
| Celecoxib |
Rofecoxib |
|
|
|
||
| Age group |
||
| 75+ |
5.34 (4.96–5.75) |
3.06 (2.83–3.30) |
| 55 to ≤74 |
3.65 (3.45–3.87) |
2.62 (2.46–2.78) |
| 18–54 |
Reference |
Reference |
| Female sex |
1.55 (1.47–1.62) |
1.45 (1.38–1.52) |
| Income level (lower) |
0.95 (0.88–1.02) |
0.83 (0.77–0.89) |
| Prior diagnosis of gastropathy |
1.21 (1.07–1.37) |
1.11 (0.97–1.27) |
| Prior gastrointestinal procedures |
1.21 (1.02–1.42) |
0.97 (0.81–1.16) |
| Prior dispensation of gastroprotective agents |
1.59 (1.48–1.71) |
1.51 (1.41–1.63) |
| Prior referral to gastroenterologist |
1.27 (1.11–1.45) |
1.19 (1.03–1.37) |
| Prior history of NSAID use: |
||
| Recent, first time |
2.25 (1.99–2.54) |
2.02 (1.79–2.29) |
| Recent, chronic |
1.68 (1.52–1.85) |
0.75 (0.68–0.84) |
| >1 to 3 months |
1.36 (1.26–1.45) |
0.48 (0.44–0.52) |
| >3 to 12 months |
0.85 (0.80–0.91) |
0.81 (0.76–0.87) |
| No use in past year |
Reference |
Reference |
| Corticosteroids |
1.11 (1.02–1.20) |
1.20 (1.11–1.31) |
| Anticoagulants |
1.61 (1.34–1.94) |
1.48 (1.23–1.78) |
| Antidepressants |
1.38 (1.28–1.48) |
1.37 (1.27–1.48) |
| Benzodiazepines |
1.18 (1.12–1.25) |
1.15 (1.09–1.22) |
| Acetaminophen |
1.39 (1.31–1.48) |
1.37 (1.28–1.45) |
| Low-dose ASA |
0.67 (0.62–0.71) |
0.58 (0.54–0.62) |
| Chronic Disease Score |
||
| 10+ |
1.26 (1.11–1.43) |
1.20 (1.06–1.37) |
| 5–9 |
1.28 (1.19–1.38) |
1.23 (1.14–1.33) |
| 1–4 |
1.25 (1.17–1.33) |
1.26 (1.18–1.34) |
| 0 |
Reference |
Reference |
| Physician specialty |
0.96 (0.90–1.03) |
0.83 (0.77–0.89) |
| Dosage |
||
| High dose |
3.36 (3.15–3.58) |
0.76 (0.70–0.82) |
| Low dose |
0.09 (0.09–0.10) |
0.73 (0.69–0.78) |
| Standard dose |
Reference |
Reference |
| Time period |
||
| January–June |
1.25 (1.16–1.34) |
0.24 (0.22–0.26) |
| July–September |
1.09 (1.00–1.19) |
0.93 (0.87–1.01) |
| October–December |
Reference |
Reference |
|
ASA, acetylsalicylic acid; NSAID, nonsteroidal anti-inflammatory drug. | ||
Moride et al. Arthritis Res Ther 2005 7:R333 doi:10.1186/ar1488 |
||